Fluoroquinolone use delays tuberculosis treatment despite immediate mycobacteriology study

European Respiratory Journal

Volumn 46, Issue 2, 2015, Pages 567-570

  Wang, Jann Yuan ^a   Lee, Chih Hsin ^b,c   Yu, Ming Chi ^b   Lee, Ming Chia ^d   Lee, Li Na ^a   Wang, Jann Tay ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d New Taipei City Hospital   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE;

ADULT; AGE; AGED; ANTIBIOTIC THERAPY; BACTERIUM CULTURE; COMORBIDITY; CONTROLLED STUDY; EMERGENCY CARE; FEMALE; HOSPITALIZATION; HUMAN; INCOME; INTENSIVE CARE; LETTER; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; NUCLEIC ACID AMPLIFICATION; PNEUMONIA; PRIORITY JOURNAL; TAIWAN; THERAPY DELAY; TIME TO TREATMENT; URBAN POPULATION; COMMUNITY-ACQUIRED INFECTIONS; DRUG EFFECTS; FOLLOW UP; LONGITUDINAL STUDY; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYCOBACTERIUM TUBERCULOSIS; PNEUMONIA, BACTERIAL; STATISTICAL MODEL; TUBERCULOSIS, PULMONARY; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CIPROFLOXACIN; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; FLUOROQUINOLONES; FOLLOW-UP STUDIES; HUMANS; LEVOFLOXACIN; LINEAR MODELS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYCOBACTERIUM TUBERCULOSIS; OFLOXACIN; PNEUMONIA, BACTERIAL; TAIWAN; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

EID: 84938871096     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00019915     Document Type: Letter

References (15)

1. Wang JY, Lee LN, Lai HC, et al. Fluoroquinolone resistance in Mycobacterium tuberculosis isolates: associated genetic mutations and relationship to antimicrobial exposure. J Antimicrob Chemother 2007; 59: 860-865.
2. Wang JY, Hsueh PR, Jan IS, et al. Empirical treatment with a fluoroquinolone delays the treatment for tuberculosis and is associated with a poor prognosis in endemic areas. Thorax 2006; 61: 903-908.
3. Migliori GB, Zellweger JP, Abubakar I, et al. European union standards for tuberculosis care. Eur Respir J 2012; 39: 807-819.
4. TB CARE I. International Standards for Tuberculosis Care (ISTC). 3rd Edn. The Hague, TB CARE I, 2014.
5. Migliori GB, Langendam MW, D'Ambrosio L, et al. Protecting the tuberculosis drug pipeline: stating the case for the rational use of fluoroquinolones. Eur Respir J 2012; 40: 814-822.
6. Migliori GB, Lienhardt C, Weyer K, et al. Ensuring rational introduction and responsible use of new TB tools: outcome of an ERS multisector consultation. Eur Respir J 2014; 44: 1412-1417.
7. Tseng YT, Chuang YC, Shu CC, et al. Empirical use of fluoroquinolones improves the survival of critically ill patients with tuberculosis mimicking severe pneumonia. Crit Care 2012; 16: R207.
8. National Health Insurance Administration, Ministry of Health and Welfare. The National Health Insurance Statistics, 2013. www.nhi.gov.tw/English/webdata/webdata.aspx?menu=11&menu-id=296&webdata-id=1942&WD-ID=296 Date last updated: March 25, 2015.
9. Lee CH, Lee MC, Shu CC, et al. Risk factors for pulmonary tuberculosis in patients with chronic obstructive airway disease in Taiwan: a nationwide cohort study. BMC Infect Dis 2013; 13: 194.
10. Wang JY, Lee MC, Shu CC, et al. Optimal duration of anti-tuberculosis treatment in diabetic patients: nine or six months? Chest 2015; 147: 520-528.
11. Migliori GB, Sotgiu G, Blasi F, et al. Towards the development of EU/EEA Standards for Tuberculosis Care (ESTC). Eur Respir J 2011; 38: 493-495.
12. Frei CR, Labreche MJ, Attridge RT. Fluoroquinolones in community-acquired pneumonia: guide to selection and appropriate use. Drugs 2011; 71: 757-770.
13. Centers for Disease Control, Department of Health, R.O.C. (Taiwan). Taiwan Tuberculosis Control Report 2013. www.cdc.gov.tw/uploads/files/201407/103228a0-fadd-47b0-b056-8dedda9fce1d.pdf Date last updated: April 2014.
14. Nyamande K, Lalloo UG, John M. TB presenting as community-acquired pneumonia in a setting of high TB incidence and high HIV prevalence. Int J Tuberc Lung Dis 2007; 11: 1308-1313.
15. Copeland KT, Checkoway H, McMichael AJ, et al. Bias due to misclassification in the estimation of relative risk. Am J Epidemiol 1977; 105: 488-495.